ListarINIBIC-ICATC - Artigos por tema "Heart failure"
Mostrando ítems 41-52 de 52
-
Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics
(MDPI, 2022-02-22)[Abstract] Hyperkalaemia is a growing concern in the treatment of patients with heart failure and reduced ejection fraction (HFrEF) as it limits the use of some prognostic-modifying drugs and has a negative impact on ... -
Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology
(Oxford Academic, 2022-01-27)[Abstract] The heart failure epidemic is growing and its prevention, in order to reduce associated hospital readmission rates and its clinical and economic burden, is a key issue in modern cardiovascular medicine. The ... -
Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry
(Oxford, 2018-10-15)[Abstract] Aim. To investigate the characteristics long-term prognostic implications (up to ∼2.2 years) of atrial fibrillation (AF) compared to sinus rhythm (SR), between acute and chronic heart failure (HF) with reduced ... -
Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery
(John Wiley & Sons, 2023-11-21)[Abstract] Aims: Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes ... -
Reduced mitochondrial pyruvate carrier expression in hearts with heart failure and reduced ejection fraction patients: ischemic vs. non-ischemic origin
(Frontiers, 2024-03-08)[Abstract] Introduction and objectives: Mitochondrial pyruvate carrier (MPC) mediates the entry of pyruvate into mitochondria, determining whether pyruvate is incorporated into the Krebs cycle or metabolized in the cytosol. ... -
Risks of ventricular arrhythmia and heart failure in carriers of RBM20 variants
(American Heart Association, 2023-10)[Abstract] Background: Variants in RBM20 are reported in 2% to 6% of familial cases of dilated cardiomyopathy and may be associated with fatal ventricular arrhythmia and rapid heart failure progression. We sought to determine ... -
Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction: a review
(Frontiers, 2021-11-11)[Abstract] Heart failure (HF) is a clinical syndrome characterized by the presence of dyspnea or limited exertion due to impaired cardiac ventricular filling and/or blood ejection. Because of its high prevalence, it is a ... -
Serum Potassium Dynamics During Acute Heart Failure Hospitalization
(Springer, 2020-10-17)[Abstract] Background. Available information about prognostic implications of potassium levels alteration in the setting of acute heart failure (AHF) is scarce. Objectives. We aim to describe the prevalence of ... -
Sex differences in heart failure with reduced ejection fraction in the GALACTIC-HF trial
(Elsevier on behalf of the American College of Cardiology Foundation, 2023-10-11)[Abstract] Background: Women with heart failure with reduced ejection fraction (HFrEF) receive less guideline-recommended therapy and experience worse quality of life than men. Objectives: The authors sought to assess ... -
Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial
(Oxford University Press, 2018-04-14)[Abstract] Aims: We aimed to determine whether treatment with sildenafil improves outcomes of patients with persistent pulmonary hypertension (PH) after correction of valvular heart disease (VHD). Methods and results: ... -
Specific Test Panels for Patients With Heart Failure: Implementation and Use in the Spanish National Health System
(De Gruyter, 2022-03-07)[Abstract] Objectives. The use of specific test panels (STP) for heart failure (HF) could help improve the management of this condition. The purpose of this study is to gain an insight into the level of implementation of ... -
Unravelling the Interplay Between Hyperkalaemia, Renin–Angiotensin–Aldosterone Inhibitor Use and Clinical Outcomes. Data From 9222 Chronic Heart Failure Patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry
(Willey Online Library, 2020-04-03)[Abstract] Aims. We assessed the interplay between hyperkalaemia (HK) and renin–angiotensin–aldosterone system inhibitor (RAASi) use, dose and discontinuation, and their association with all‐cause or cardiovascular death ...